1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Noxopharm Limited

Noxopharm Limited

NOXOF
Noxopharm LimitedUS flagOther OTC
0.05
USD
- -
- -
14.78MMarket Cap
Noxopharm Limited
NOXOF
(Other OTC)

Recent

price

0.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.03
-0.15
-0.08
- -
-0.04
-0.06
-0.05
-0.01
Basic EPS, GAAP
- -
-0.03
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.03
0.05
-0.03
0.07
0.12
0.05
0.01
0.02
Book Value per Share
- -
0.03
0.08
-0.01
0.09
0.15
0.08
0.03
0.02
Tangible Book Value per Share
- -
88
119
138
138
264
291
292
292
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-3
-18
-11
- -
-9
-19
-15
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
6
2
13
-2
6
26
19
8
4
Working Capital
- -
- -
3
- -
- -
- -
- -
- -
- -
LT Debt
6
2
10
-1
13
41
24
9
5
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-74.11
-411.67
- -
- -
-44.03
-77.58
-163.59
-100.22
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-182.68%
-39.44%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
648.34%
-76.24%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
-0.06
2023
- -
- -
- -
- -
-0.05
2024
- -
- -
- -
- -
-0.01

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Inhibrx Biosciences, Inc. (INXB)
Kronos Bio, Inc. (KRON)
Biotron Limited (BIT.AX)
Ryvu Therapeutics S.A. (RVU.WA)
Polus BioPharm Inc. (007630.KS)
CNS Pharmaceuticals, Inc. (CNSP)
Business
Noxopharm Limited (ASX:NOX; OTC:NOXOF) is an Australian clinical-stage biotechnology company focused on discovering and developing novel oncology and anti-inflammatory drug candidates, as well as proprietary technologies to enhance mRNA vaccines; its core platforms include Chroma™ for oncology applications such as the CRO-67 dual-cell therapy targeting pancreatic cancer and associated stromal barrier cells, and Sofra™ for inflammation, autoimmunity, and mRNA vaccine enhancement via candidates like SOF-VAC™, which reduces inflammatory side effects such as fever and fatigue in mRNA-based therapeutics including COVID vaccines, alongside SOF-XX and SOF-SKN™ for autoimmune diseases like lupus, psoriasis, and chronic inflammation. The company maintains a major shareholding in US-listed Nyrada Inc. (ASX:NYR), which develops drugs for cardiovascular and neurological disorders. Founded in 2015 and headquartered in Sydney, New South Wales, Noxopharm conducts operations primarily in Australia through in-house R&D and strategic collaborations with institutions including the Hudson Institute of Medical Research and UNSW Sydney. In recent developments, Noxopharm received a NSW Government grant in November 2025 to support its UNSW collaboration, announced preclinical progress and new clinical trial preparations for SOF-SKN™ targeting chronic inflammatory diseases in September 2025, secured convertible note funding, entered multiple material transfer agreements to explore commercial opportunities, generated nearly $2.5 million in non-dilutive funds from Nyrada share sales, discontinued its Veyonda® DARRT-2 and CEP-2 clinical trials in 2023 to prioritize preclinical platforms amid patient recruitment challenges and cost efficiencies, reduced headcount by 40% as part of a strategic operational restructuring, and continues supplying Veyonda® for the investigator-initiated IONIC trial while advancing robust intellectual property protections around its assets.